A study published in Bone Marrow Transplantation shows that allogeneic hematopoietic cell transplantation (allo-HCT) stands as a curative option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
In this retrospective multicenter study, researchers assessed 140 patients with R/R DLBCL who underwent allo-HCT from March 1995 to November 2018.
According to the results, the three-year event free survival (EFS) and overall survival (OS) rates following allo-HCT were 38% and 44%, respectively. The researchers observed that non-relapse mortality (NRM) at day 100 was 19%, with disease at allo-HCT (hazard ratio [HR], 1.95; P=0.039) (HR, 2.19; P=0.019), HCT-CI ≥2 (HR, 2.45; P=0.002) (HR, 2.33; P=0.006) and donor age >37 years (HR, 2.75; P=0.014) (HR, 1.98; P=0.043) were the only independent variables both for progression-free survival (PFS) and OS, respectively. The researchers noted that NRM was significantly modified by HCT-confidence interval (CI) ≥ 2 (HR, 4.8; P=0.008), previous allo-HCT (HR, 4.4; P=0.048) and grade III-IV acute graft-versus-host disease on day 100 (HR, 6.13; P=0.016).
“Our data confirmed that allo-HCT is a curative option for patients with R/R DLBCL, displaying adequate results for fit patients with chemo-sensitive disease receiving an allo-HCT from a young donor,” the researchers concluded.